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Prospective Evaluation of Two Dosing Equations for 
Theophylline in Premature Infants 
Varsha Bhatt-Mehta, Pharm.D., Steven M. Donn, M.D., M. Anthony Schork, Ph.D., 
Susan Reed, Pharm.D., and Cary E. Johnson, Pharm.D. 
Study Objectives. To evaluate prospectively the ability of two equations that 
we previously derived to predict maintenance theophylline dosages that 
provide a serum theophylline concentration (STC) of 8 pg/ml, the 
midtherapeutic range for treating apnea of prematurity; and to determine 
the number of further dosage adjustments and STC determinations 
required to achieve the target concentration in infants in whom it was not 
achieved initially. 
Design. Prospective study. 
Setting. A 37-bed neonatal intensive care unit. 
Patients. Fifty-four infants 27-34 weeks’ gestational age requiring 
intravenous hydrous aminophylline. 
Interventions. Patients received a loading dose of 6 mg/kg intravenous 
aminophylline, followed by a maintenance dosage calculated using one of 
the two derived equations. The basis for equation selection was the 
gestational age of the patient. 
Measurements and Main Results. Patients were stratified into two age 
groups: 27-30 weeks’ gestational age (34 infants) and 31-34 weeks’ 
gestational age (20 infants). The overall success rate for both equations in 
achieving the target concentration was 74%. When infants were stratified 
by gestational age, those dosed by Equation 1 had a 76% success rate and 
those dosed by Equation 2 had a 65% success rate. Overall, 14 of 54 
infants received an average of 1.2 dosage adjustments. This represents 
more than a 50% reduction in the number of adjustments made before 
introduction of these equations. 
Conclusions. The ability of our previously derived equations to produce an 
STC within the midtherapeutic range for treating apnea of prematurity was 
demonstrated in the majority of patients studied (74%). Further, the 
number of subsequent dosage adjustments required to attain the target STC 
in infants who had failed to achieve this STC initially was significantly less 
than using older, more traditional regimens. 
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death if left untreated.2 The frequency of apnea 
increases with decreasing weight. It occurs in 
25% of infants less than 2500 g and in 84% of 
infants less than 1000 g.’,3 It appears to decrease 
exponentially with increasing gestational age, 
occurring in the majority of infants born at 30 
weeks’ or less.4 
Apnea can be treated with supportive or 
pharmacologic measures. Supportive therapy 
consists of sensory stimulation, oxygen adminis- 
tration, continuous positive airway pressure, or 
mechanical ~ent i la t ion.~-’  Pharmacologically, 
methylxanthines are the primary agents of 
choice, and doxapram hydrochloride may be a 
second-line agent.5 Caffeine and theophylline 
st imulate the central  respiratory center. 
Theophylline is the primary treatment for apnea 
of prematurity in the United States, primarily due 
to the availability of intravenous and oral 
preparations commercially, whereas caffeine 
preparations st i l l  require extemporaneous 
compounding. This sometimes becomes 
cumbersome at an institutional level and also 
does not guarantee product uniformity from one 
institution to another. 
The mechanism of action of theophylline 
includes alteration of the sensitivity of the 
medullary respiratory center to carbon dioxide 
and improvement of contractility of respiratory 
muscles and recovery from fa t ig~e .~  Theophylline 
decreases the frequency of apnea by increasing 
respiratory minute volume and the ventilatory 
response to carbon dioxide, and decreasing the 
frequency of hyperoxic and hypoxic episodes.’, 
With caffeine or theophylline, a significant 
decrease in the number and severity of apneic 
episodes can usually be seen within 24-48 hours, 
and continued treatment leads to complete 
control of primary apnea of prematurity in most 
cases.5 Serum theophylline concentrations (STC) 
in the range of 6-13 pg/ml are effective.’, lo, l1 
The drug’s toxic effects are dose related and 
include gastrointestinal, cardiovascular, and 
neurologic symptoms, with intractable seizures at 
STC exceeding 20 pg/ml.12 
Although theophylline has been used in the 
treatment of apnea of prematurity for over 2 
decades, no consensus exists as to the best 
method of predicting maintenance dosages in 
premature infants. Numerous small studies 
evaluated the agent’s disposition in premature 
infants.lO. 11, 13-19 Th e general dosing guideline 
they arrived at is a loading dose of 5.0-6.0 mgkg 
followed by a maintenance dosage of 1.1-2.0 
mgkg every 12 hours. Earlier” we compared the 
accuracy, precision, and reliability of two 
published equations using postnatal age (PNA) 
as a variable 21, 22 to calculate the maintenance 
dosage of theophylline based on  patients’ 
disposition characteristics. We found that the 
equations were unreliable for predicting safe and 
effective maintenance dosages in premature 
infants. Subsequently we used the collected data 
to arrive a t  two new equations specific to the 
premature infant (Appendix) and targeted at 
achieving an STC of 8 pg/ml. 
We prospectively evaluated the accuracy with 
which the equations derived in our previous 
studyZo were able to predict maintenance 
theophylline dosages that provide an STC of 8 
pg/ml, the midtherapeutic range for treating 
apnea of prematurity. A second ai was to 
determine the number of further dosage 
adjustments and STC determinations required to 
achieve the target concentration in infants in 
whom i t  was not  aphieved initially. The 
hypothesis was that the new equations would 
produce an STC of 8 pg/ml or more in at least 
66% of patients. Allowing infants to reach a 
therapeutic STC faster would reduce the time 
spent being apneic and hypoxemic, thus reducing 
morbidity from such events, and would require 
fewer dosage adjustments and subsequent STC 
determinations, thus decreasing blood loss and 
the need for transfusions, as well a s  risk of 
infection due to numerous venipunctures or 
heelsticks. 
F 
Methods 
Fifty-four infants 27-34 weeks’ gestational age 
requiring intravenous hydrous aminophylline 
were included in the study. This sample size 
allowed for observing a 15% or more decrease in 
the number of STC determinations in patients 
who achieved an STC of less than 8 pg/ml with 
an initial maintenance dosage. The new 
equations were designed to produce an STC of 8 
pg/ml with the initial maintenance dosage. The 
exclusion criterion was gestational age less than 
27 weeks or greater than 34 weeks. 
At our institution, intravenous aminophylline 
is routinely given before endotracheal extubation 
in premature infants 34 weeks’ gestational age or 
less based on  a previous report.23 Since 
theophylline is the standard treatment for apnea 
of prematurity and all premature infants at our 
insti tution follow the standard protocol, 
informed consent was not sought before entering 
patients into the study. However, the approval of 
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the institutional review board was obtained. 
All infants requiring periextubation amino- 
phylline were enrolled and stratified into two age 
groups: 27-30 (n=34) and 31-34 (n=20) weeks’ 
gestational age. These were based on the results 
of our previous study where the correlation 
between theophylline dosage and gestational age 
was best when infants were divided into less than 
and greater than 30 weeks’ gestational age. The 
upper limit of 34 weeks was set based on our 
protocol. 
All premature infants were given a standard 6- 
mg/kg intravenous loading dose of aminophylline 
dihydrate. For the younger group, the mainte- 
nance dosage of aminophylline was calculated 
based on Equation 1 and for the older group it 
was calculated based on Equation 2. The 
equations allowed the maintenance dosages to be 
calculated a s  mg/kg/day of theophylline. 
Adjustments were then made to allow for 
conversion from theophylline to aminophylline 
and also for the infants’ weight. The final dosage 
was derived as mg/day of aminophylline. It was 
then divided into three equal doses that were 
administered at  8-hour intervals. The first 
maintenance dose was administered 8 hours after 
the loading dose. The loading dose as well as all 
maintenance doses were infused over 15-30 
minutes using a syringe infusion pump. 
Trough STCs were measured in all subjects just 
before the fourth maintenance dose of 
aminophylline. The STC was analyzed by 
fluorescence polarization immunoassay (TDx; 
Abbott Laboratories, Chicago, IL). Infants were 
followed as long as they were receiving intra- 
venous aminophylline in the neonatal intensive 
care unit. Those not within the target range were 
investigated for possible etiologies for the 
subtherapeutic STC. Dosage adjustments made 
were recorded and new STCs were determined 
just  before the fourth newly adjusted dose. 
Subjects were monitored for apnea and signs of 
theophylline toxicity. Any concurrent drug 
therapy or other treatments given for apnea of 
prematurity were recorded. Any tests performed 
to evaluate the apneic episodes were followed. 
Data collected on each subject were PNA, 
gestational age, weight ( a t  the beginning of 
treatment and around assessment of STC), STC, 
theophylline dosage based on  equation 
calculations, and any dosage adjustments that 
were made to achieve therapeutic STC. Results 
of liver function tests and other treatments that 
may affect STC were also recorded. 
Descriptive statistics including means and 
Table 1. Patient Demographics” 
Gestational Postnatal Age Weight at 
Age at Treatment Treatment 
(wks) (wks) (wks) (kg) 
27-30 28.99 f 1.44 0.86 f 0.83 1.31 f 0.24 
31-34 32.11 0.95 0.33 * 0.16 1.61 f 0.33 
“Expressed as mean f SD. 
standard deviations were computed. The 
frequency with which the two equations 
produced maintenance theophylline dosages with 
STC within the desired therapeutic range of 8 
pg/ml or greater was determined. Paired 
Student’s t test and repeated measures analysis of 
variance (ANOVA) were used to compare the 
new equations with the previously evaluated 
equationsZo to determine if there was a 
statistically significant difference in the success 
rate. 
We also calculated each patient’s steady-state 
clearance (mg/kg/hr) based on the actual dosage 
received (mg/kg/day) and measure4 steady state 
STC (mg/L). Using thig Osteady-state clearance 
and the dosage generated by equation A or B, the 
steady-state predicted STC was calculated for 
each patient. This predicted STC was plotted 
against the mg/kg/day dosage calculated using 
each equation as well as the dosages obtained 
with the new equations. 
Results 
The 54 infants all received a loading dose of 
intravenous aminophylline 6 mg/kg (Table 1). 
Although Equations 1 and 2 were designed to 
achieve an STC of 8 pg/ml, any serum concen- 
tration greater than 7.2 pg/ml was considered a 
therapeutic success because of a potential 10% 
instrumental variation in the analysis of serum 
theophylline concentrations in our laboratory. 
Only four infants in the younger group had an 
STC between 7.2 and 8 pg/ml and were classified 
as therapeutic successes. Twenty infants in this 
group who were declared therapeutic successes 
achieved an STC of 8 pg/ml or greater with the 
initial regimen based on Equation 1. No such 
patients were identified in the older group. That 
is, all infants who were therapeutic successes 
achieved an STC of 8 pg/ml or greater with the 
initial maintenance dosage calculated using 
Equation 2. We realize that this 7.2 pg/ml value 
(for a lower limit of 8 pg/ml) is not ideal, bGt it is 
real, and clinicians must be aware of such 
practical problems and take them into 
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consideration when interpreting laboratory data. 
Whereas the equations were designed to 
achieve an STC of 8 pg/ml, some patients would 
achieve an STC greater than that due to inter- 
patient variability in theophylline metabolism. 
Thus, a dosing regimen was considered to be a 
therapeutic success if the STC achieved was 8 
pg/ml or greater and adjusted to 7.2 pg/ml as 
explained. The overall success rate for both 
equations in achieving a level of 7.2 pg/ml or 
greater was 74%. When infants were stratified by 
gestational age, those dosed by Equation 1 had a 
76% success rate and those dosed by Equation 2 
had a 65% success rate. 
A second aim of this study was to evaluate the 
number of dosage adjustments required by 
patients who did not achieve the target STC with 
the initial regimen. Of the 34 infants 27-30 
weeks’ gestational age, 10 had dosages adjusted 
1-2 times to achieve the target concentration. 
Four of these 10 had an STC greater than 7.2 
pg/ml but were symptomatic with evidence of 
apnea or periodic breathing. Of the remaining 
six, five were symptomatic with an STC less than 
7.2 pg/ml. The tenth infant had an STC less than 
7.2 pg/ml but was not symptomatic. 
Of the 20 infants age 31-34 weeks’ gestational 
age, 4 had dosages adjusted after the initial 
regimen. Of these four, two were symptomatic 
with evidence of apnea and were therapeutic 
failures with an STC less than 7.2 pg/ml. In the 
remaining two, the STC was greater than 7.2 
pg/ml in one and below target concentration in 
the other. 
Overall, 14 of 54 patients received an average 
of 1.2 dosage adjustments. This represents more 
than a 50% reduction in  the number of 
adjustments that were made before introduction 
of these equations. 
We used the patient population from the 
prospective study and predicted the mg/kg/day 
dosage that we would achieve using the 
equations of Hendeles et a124 (Equation A) and 
Nassif et al” (Equation B). Both equations were 
applied to both groups. The mean dosage 
generated from these equations was compared 
with the mean dosage generated by the new 
equations using repeated measures ANOVA 
(Table 2).  All three mean dosages were 
significantly different (p<0.05).  Pairwise 
Student’s t test was used to compare the mean 
dosage from the new equations with each of the 
mean dosages from Equations A and B for each 
group of patients. The means were again 
significantly different for the younger group 
Table 2. Success Rates of Dosing Equations from the 
Retrospective Study” and Current Study Using Patient 
Demographics from the Prospective Study Population 
Mean Dosage 
Using Patient 
Demographics 
Equations Prospective Study ANOVA and 
Compared (mg/kg/day) Paired t Test 
gestational age Paired t test 
from the Repeated Measures 
27-30 wks’ I ANOVA p c 0.05 
Equation 1 9.8 * 2.2 1 vs A p=O.OOO 
Equation A 5.15 * 0.16 1 vs B p=0.0004 
Equation B 8.24 * 0.24 A vs B p=O.OOO 
31-34 wks’ ANOVA p<0.05 
gestational age Paired t test 
Equation 2 10.4 * 2.2 2 vs A p=O.OOO 
Equation A 5.07 * 0.04 2 vs B p=0.0002 
Equation B 8.1 f 0.05 A vs B p=O.OOO 
(p=0.0004) and the older group (p=0.0002). 
Figures 1 and 2 are scatter plots of dosages 
calculated by the new equations and the 
corresponding plasma STCs. Figures 3-6 show 
the predicted steady-state STC that would have 
resulted if the dosage recommended by Equation 
A or B was administered. The mean predicted 
concentrations were 6.5 _+ 1.3 pg/ml (27-30 wks) 
and 6.9 _+ 1.6 pg/ml (31-34 wks) for Equation A 
and 10.4 _+ 2.1 pg/ml (27-30 wks) and 11.3 k 2.5 
pg/ml (31-34 wks) for Equation B. The 
corresponding STC values for the new equations 
were 8.3 k 2 and 8.3 k 1.8 pg/ml, respectively, for 
the two age groups. 
Most of the infants in both age groups dosed 
based on Equation B would have been in the 
acceptable range of 7.2-12 pg/ml range. 
Although this result compares reasonably well 
with STC obtained using the new equations, a 
fair number of patients still would achieve 
concentrations as high as 17 pg/ml, which are 
considered to be in the toxic range for treatment 
of apnea of prematurity. The STC produced by 
Equation A were consistently below 7.2 pg/ml. 
Concomitant drugs during the study period 
included antibiotics and, occasionally, pheno- 
barbital. We give phenobarbital routinely for 
intraventricular hemorrhage prophylaxis in all 
premature infants weighing less than 1800 g.25 
However, this is a limited time protocol and 
includes a loading dose of 20 mgkg followed by 
standard maintenance dosage of 5 mg/kg/day for 
4 days after birth.  This short  course of 
phenobarbital is insufficient to produce enzyme 
induction.” Most infants had stopped receiving 
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phenobarbital by the time they were ready for Dosage guidelines currently available for 
calculating theophylline maintenance dosages 
have to be evaluated for administration for apnea 
extubation. 
Discussion of prematurity, since the studies included widely 
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Figures 1-6. Scatter plots of calculated serum theophylline concentrations vs recommended dosages for the new equations 
(plots 1 and 2) and the Hendeles et a1 (3  and 4) and Nassif et a1 (5 and 6) equations. Horizontal lines in the plot at 
concentrations of 7.2 and 12 pdml represent the therapeutic range aimed at in this study and is the generally accepted range 
for treatment of apnea of prematurity. 
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variable patient populations, dosing intervals, 
and routes and methods of administration 
(intermittent vs continuous infusions).21- 2 4 3  26 
Most of the guidelines are based on the clearance 
of theophylline in newborn infants. Clearance 
depends on volume of distribution and the 
elimination rate constant, both of which change 
with maturation." Previous studies evaluating 
theophylline pharmacokinetics in newborn 
infants showed that the most important variables 
for predicting theophylline clearance are weight 
and PNA. Both are related to the development of 
the newborn and determinants of the functional 
activity of the eliminating system.'O> 21, 27-29 
Weight and gestational age are highly correlated, 
indicating that factors such as gestational age 
should also be important predictors of 
theophylline clearance.l8 
Since maturation is a continuous process and 
occurs at a variable rate in newborns, the volume 
of distribution and elimination rate constant 
reported in the literature vary depending on the 
ages of the infants. Several studies developed 
empiric dosage guidelines based on weight and 
pharmacokinetics. These dosages vary from 1.1 
mg/kg every 8 hours to 1-4 mg/kg every 12 
hours.'O- '' Current recommendations of the 
Food and Drug Administration consist of a 
loading dose equal to 1 mgkg for every 2-pg/ml 
desired increase in  STC and a maintenance 
dosage of 1 mgkg every 12 hours in premature 
infants 40 weeks' postconception age (PCA) or 
younger, or 1-2 mgkg every 12 hours for term 
infants (either at  birth or 40 wks' PCA).30 
However, these guidelines have been criticized as 
too conservative, often resulting in STCs below 6 
pg/m1.26x 31 
Alternatively, dosing equations derived for 
administering theophylline to asthmatic patients 
were used in an attempt to individualize dosages 
in infants with apnea of prematurity. In a study 
of infants 6-48 weeks' PNA with asthma, an 
equation was generated by linear regression to 
express a relationship between PNA and oral 
theophylline requirement." Another such 
equation incorporates PNA as a variable and aims 
for an  STC between 7-13 pg/rnl." In a 
retrospective study of 52 infants 4.5-54.3 weeks' 
PNA, three equations were compared that 
incorporated either PNA or PCA to calculate 
theophylline maintenance dosages. The patients 
received theophylline by continuous intravenous 
infusion. The observed theophylline clearance 
and the dosages derived from each equation were 
used to determine the projected steady-state STC. 
Of these equations, the two based on PNA were 
superior, with one better at achieving the greatest 
proportion of STC within the therapeutic range 
of 10-20 pg/ml and the other better when serum 
concentrations less than 10 pg/ml were desired.32 
In summary, the majority of methods for 
dosing theophylline for the treatment of apnea of 
prematurity are empiric. They are based primarily 
on weight, or dosag5s are calculated from 
equations incorporating PNA in infants requiring 
theophylline for the treatment of asthma. The 
age range of the patients and the therapeutic 
STCs obtained in these studies are different from 
those involved in apnea of prematurity. 
Proposed dosing guidelines based on 
gestational age, weight, and PNA were able to 
produce a therapeutic STC in the majority of 
premature infants evaluated. The overqll success 
rate for the two equations of 74% was consistent 
with the hypothesis that the equations would 
produce an STC of 8.0 pg/ml in at least 66% of 
these premature infants. Using patient data from 
the prospective study, all three equations were 
statistically different when compared using 
repeated measures ANOVA for both age groups. 
Equation B performed much better than Equation 
A in predicting a daily dose closer to the new 
equations. 
This result is different from our retrospective 
study, in which Equation A was much more 
successful than Equation B in producing target 
STC. There are several reasons for this. The 
retrospective and prospective equations were 
compared for their ability to produce the target 
STC using different patient populations; however, 
when patient data from the prospective study 
were fit to the previous Equations A and B, the 
ability of these equations to predict the dosage 
that would produce an STC close to that 
produced by Equation 1 or 2 was determined. 
Equation B did not  perform well in  the 
retrospective study because our target STC was 8 
pg/ml and  i t  produced a higher STC, thus 
requiring us  to declare a lot  of patients as 
failures. In the prospective study, the STC was 8 
pg/ml or higher, up to a maximum of 12 pg/ml 
considered the acceptable normal range for 
treatment of apnea of prematurity, and increasing 
the target range increased the success rate. 
Finally, none of the equations in the retrospective 
study incorporated gestational age as a variable, 
and this seems to have major influence on the 
dosage generated by the new equations. 
The greater than 50% reduction in the number 
of subsequent dosage adjustments necessary to 
EQUATIONS FOR DOSING THEOPHYLLINE IN PREMATURE INFANTS Bhatt-Mehta et al 775 
achieve the desired STC in infants with an initial 
low STC was also consistent with the hypothesis 
that these equations would result in 15% or more 
reduction in the number of dosage adjustments 
required after the initial dose. 
Attempts to identify the cause of STC less than 
7.2 pg/ml in both age groups did not reveal any 
obvious reasons other than interindividual 
variation. The PNA and gestational age were 
comparable for all infants in each group who had 
STC below the desired level after the initial 
regimen and received dosage adjustments. 
Some of these infants were receiving simul- 
taneous phenobarbital, but this was not different 
from the infants who had achieved STC of 7.2 
pg/ml or higher with the initial dose. Pheno- 
barbital induces theophylline metabolism in 
adults after administration for at least 1 month.33 
Several investigators showed no to minimal effect 
of phenobarbital on theophylline clearance in 
children, especially with short courses such as 
the given to our patients for prophylaxis against 
intraventricular hemorrhage.34* 35 Although 
phenobarbital is thought to be a nonspecific 
inducer of the entire cytochrome P-450 system in 
adults,36 such effects have not been observed in 
newborn infants receiving short-term treatment. '* 
The disposition of theophylline in premature 
and term newborn infants differs greatly from 
that of children and adults because of altered 
metabolism. In newborn infants, renal elimination 
of unchanged drug and methylation of 
theophylline to caffeine are the predominant 
pathways of elimination, whereas the oxidation 
and demethylation pathways leading to the usual 
metabolites seen in adults are barely functioning.12 
Immaturity of the hepatic cytochrome P-450 
mixed-function oxidase system is the reason for 
this altered metabolism and results in a very long 
half-life of theophylline in infants (13-29 hrs).l. 5 9  
The half-life of caffeine is also prolonged and 
can range from 100-200 hours in a newborn.12 
Metabolic rates are highly variable between and 
within newborn infants secondary to the different 
degrees of maturity and rapid changes in hepatic 
enzyme systems5 As the infant matures, the half- 
life of theophylline decreases. The percentage of 
theophylline converted to caffeine remained 
unchanged in  infants 28-42 weeks PCA.38 
Caffeine and theophylline are both active drugs, 
with synergistic efficacy and toxicities further 
complicating the dosing of theophylline in the 
newborn.12 Overall, the small number of infants 
in each group who did not achieve the desired 
12, 29. 37 
STC with initial dosing regimen is best explained 
by interindividual variation in theophylline 
metabolism in the first year of life. 
Equations that can consistently achieve an STC 
within the therapeutic range are valuable for use 
in  preterm infants because of the narrow 
therapeutic range and the interindividual 
variations in metabolism of theophylline in the 
newborn. By successfully achieving a level of 8.0 
pg/ml in 72% of infants gestational age 27-34 
weeks, the need for numerous SIC determinations 
is reduced. Reaching a therapeutic STC quickly 
benefits the preterm infant by reducing delays in 
attaining adequate drug concentrations in  
plasma. Decreasing the number of blood draws 
saves both time and the cost of determining the 
levels. Also, the infant is spared the trauma of 
blood sampling, the loss of blood for testing, and 
a possible reduction in  the number of 
transfusions and hence blood donor exposures. 
Conclusion 
The equations evaluated in this study produced 
results consistent with our  hypothesis. A 
significant number of infants still did not achieve 
therapeutic STC and remained symptomatic. No 
specific patient characteristics other than 
interindividual variations in  theophylline 
metabolism could be identified as cause of failure 
to achieve target concentrations with initial 
maintenance dosage. Appropriate use of these 
equations should result in target STCs in the 
majority of premature infants. 
Appendix. Dosing Regimen and Equations 
Loading dose: Aminophylline 6 mg/kg for all patients 
~~ 
Maintenance dosages: 
Equation 1 (27-30 wks): 
Equation 2 (31-34 wks): 
mg/kg/day theophylline = 5.81 - (0.02 x PNA in wks) 
mg/kg/day theophylline = 4.82 + (0.28 x PNA in wks) 
The dosage was converted to aminophylline and multiplied 
by the patient's weight, and the resultant dosage was 
divided into three equal parts and administered every 8 
hours. 
Previously evaluated equations: 
Equation A: 
Equation B: 
mg/kg/day theophylline = ((0.2 x PNA in wks) + 51.22 
mg/kg/day theophylline = ((0.3 x PNA in wks) + 81.*l 
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